原花青素 | 20347-71-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 中文名称: 原花青素
• 中文别名: 马来酸异丙嗪
• 英文名称: Procyanidin
• 英文别名: proanthocyanidin；proanthocyanidins；2-(3,4-dihydroxyphenyl)-2-[[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl]oxy]-3,4-dihydrochromene-3,4,5,7-tetrol
• CAS: 20347-71-1
• 化学式: C₃₀H₂₆O₁₃
• 分子量: 594.529
• InChiKey: HGVVOUNEGQIPMS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  43
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  230
• 氢给体数：
  10
• 氢受体数：
  13

文献信息

• [EN] METHODS OF INHIBITING SARS-COV-2 REPLICATION AND TREATING CORONAVIRUS DISEASE 2019<br/>[FR] PROCÉDÉS D'INHIBITION DE LA RÉPLICATION DU SRAS-COV-2 ET DE TRAITEMENT DE LA MALADIE À CORONAVIRUS 2019
  申请人：PFIZER

  公开号：WO2021176369A1

  公开（公告）日：2021-09-10

  The invention relates to methods of treating COVID-19 in a patient by administering therapeutically effective amounts of certain SARS-CoV-2 inhibitor compounds or pharmaceutical compositions containing them to a patient in need thereof. The invention also relates to inhibiting SARS-CoV-2 coronavirus viral replication activity comprising contacting SARS-CoV-2-related coronavirus protease with a therapeutically effective amount of a SARS-Cov-2 protease inhibitor, such as a SARS-Cov-2 3CL protease inhibitor and compositions comprising the same

  该发明涉及通过向需要治疗的患者施用特定SARS-CoV-2抑制剂化合物或含有它们的药物组合物的治疗有效量来治疗COVID-19的方法。该发明还涉及抑制SARS-CoV-2冠状病毒病毒复制活性，包括将SARS-CoV-2相关冠状病毒蛋白酶与SARS-Cov-2蛋白酶抑制剂的治疗有效量接触，如SARS-Cov-2 3CL蛋白酶抑制剂以及包含相同的组合物。
• [EN] NITRILE-CONTAINING ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX CONTENANT DU NITRILE
  申请人：PFIZER

  公开号：WO2021250648A1

  公开（公告）日：2021-12-16

  The invention relates to compounds of Formula (I'') wherein R, R1, R2, R3, p, q and q' are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS- CoV-2 with the compounds.

  该发明涉及公式(I'')中的化合物，其中R、R1、R2、R3、p、q和q'的定义如本文所述，包括该化合物的药物组合物，通过向患者施用治疗有效量的化合物来治疗冠状病毒感染，如COVID-19的方法，以及使用该化合物抑制或预防冠状病毒如SARS-CoV-2的复制的方法。
• [EN] ANTIVIRAL HETEROARYL KETONE DERIVATIVES<br/>[FR] DÉRIVÉS D'HÉTÉROARYL CÉTONE ANTIVIRAUX
  申请人：PFIZER

  公开号：WO2022013684A1

  公开（公告）日：2022-01-20

  The invention relates to compounds of Formula (I) wherein R1, R2, p, m, A, Z1, Z2, Z3 and Z4 are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.

  该发明涉及式（I）的化合物，其中R1、R2、p、m、A、Z1、Z2、Z3和Z4如本文所定义，包括该化合物的药物组合物，通过给患者施用治疗有效量的该化合物来治疗COVID-19的方法，以及使用该化合物抑制或预防SARS-CoV-2的复制的方法。
• Nitrile-containing antiviral compounds
  申请人：Pfizer Inc.

  公开号：US11351149B2

  公开（公告）日：2022-06-07

  The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

  本发明涉及式 I″ 的化合物 其中R、R1、R2、R3、p、q和q′如本文所定义；包含该化合物的药物组合物；通过施用治疗有效量的该化合物治疗患者冠状病毒感染如COVID-19的方法；以及用该化合物抑制或防止冠状病毒如SARS-CoV-2复制的方法。
• NITRILE-CONTAINING ANTIVIRAL COMPOUNDS
  申请人：Pfizer Inc.

  公开号：EP3953330A1

  公开（公告）日：2022-02-16